Tag: Drugs
Search News
KEYNOTE-522: Immune therapy for breast cancer
30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more
Antibody therapy in pancreatic cancer
31st July 2019
Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion. Called avb6, the protein is present on the surface of more than 80 per cent of pancreatic ductal adenocarcinoma – the most common form of pancreatic cancer – and is vital to increase the successful growth and spread of the tumour cells.
Read more
New research funded by PCRF
19th July 2019
The Pancreatic Cancer Research Fund is supporting two new research projects at the Barts Cancer Institute, Queen Mary University of London. The projects, led by Professor Hemant Kocher and Dr Gunnel Halldén, will aim to identify ways to enhance the efficacy of treatments for pancreatic cancer, to ultimately help those affected by this devastating disease.
Read more
2019 ASCO Annual Meeting
4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more
AR alterations in prostate cancer
16th May 2019
Recent findings from a study published in JAMA Oncology have identified genetic markers within blood samples which may indicate whether patients with prostate cancer will respond to hormonal therapies. The study may represent an important step forward for the development of more personalised treatments for advanced prostate cancer.
Read more
Therapy for high-grade glioma
2nd April 2019
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.
Read more